Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Dynavax Technologies Corporation DVAX NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
71/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$31.00
+100%

Dynavax Technologies Corporation (DVAX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $15.50. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is DVAX = $31 (+100% upside).

Financials: revenue is $277M, +5.3%/yr average growth. Net income is $27M, growing at +235.8%/yr. Net profit margin is 9.9% (thin). Gross margin is 82.2% (+21.7 pp trend).

Balance sheet: total debt is $254M against $597M equity (Debt-to-Equity (D/E) ratio 0.43, conservative). Current ratio is 10.8 (strong liquidity). Debt-to-assets is 25.8%. Total assets: $986M.

Analyst outlook: 9 / 11 analysts rate DVAX as buy (82%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 83/100 (Pass), Past 75/100 (Partial), Health 67/100 (Partial), Moat 70/100 (Pass), Future 94/100 (Pass), Income 45/100 (Partial).

$31.00
▲ 100% Upside
Average Price Target
The 12-month price target for Dynavax Technologies Corporation is $31.00.

DVAX SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 62/100
Valuation — P/E, PEG, Forward PEG
GROWTH 83/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 45/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DVAX

✓
VALUE Pass
62/100
DVAX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $31, implying +100% from the current price $16. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
83/100
DVAX: +5.3%/yr revenue is, +235.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
DVAX: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet DVAX: Debt-to-Equity (D/E) ratio 0.43 (conservative), Current ratio is 10.8 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
DVAX: Gross margin is 82.2% (+21.7 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 9 / 11 analysts rate DVAX as buy (82%). Analyst consensus target is $31 (+100% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
~
INCOME Partial
45/100
DVAX: Net profit margin is 9.9%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range9.2-15.73
Volume5.66M
Avg Volume (30D)3.16M
Market Cap$1.82B
Beta (1Y)0.93
Share Statistics
EPS (TTM)0.21
Shares Outstanding$130.05M
IPO Date2004-02-19
Employees405
CEORyan Spencer
Financial Highlights & Ratios
Revenue (TTM)$277.25M
Gross Profit$227.8M
EBITDA$45.7M
Net Income$27.31M
Operating Income$-4.12M
Total Cash$713.83M
Total Debt$254.42M
Net Debt$158.53M
Total Assets$986.26M
Price / Earnings (P/E)73.8
Price / Sales (P/S)6.56
Analyst Forecast
1Y Price Target$31.00
Target High$31.00
Target Low$31.00
Upside+100.0%
Rating ConsensusBuy
Analysts Covering11
Buy 82% Hold 9% Sell 9%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS2681582019

Price Chart

Track all markets on TradingView
DVAX
Dynavax Technologies Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
9.20 52WK RANGE 15.73

People Also View

ITCI
ITCI
Intra-Cellular Therapies, Inc.
$131.87
+0.00%
 NBIX
NBIX
Neurocrine Biosciences, Inc.
$130.81
+3.55%
 ALKS
ALKS
Alkermes plc
$33.87
+0.36%
 LNTH
LNTH
Lantheus Holdings, Inc.
$82.74
+1.31%
 DCPH
DCPH
Deciphera Pharmaceuticals, Inc.
$25.59
+0.08%
 ANIP
ANIP
ANI Pharmaceuticals, Inc.
$78.29
-0.03%
 COLL
COLL
Collegium Pharmaceutical, Inc.
$35.64
+0.06%
 PCRX
PCRX
Pacira BioSciences, Inc.
$23.75
-1.29%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message